Hereditary haemochromatosis: Diagnosis and management in the gene era

Liver

Volumn 19, Issue 2, 1999, Pages 73-80

  Olynyk, John K ^a,b  

^a FREMANTLE HOSPITAL   (Australia)

^b University Department of Medicine   (Australia)

Author keywords

Diagnosis; Hereditary haemochromatosis; Iron; Liver; Screening

Indexed keywords

IRON;

CAUCASIAN; EARLY DIAGNOSIS; GENE MUTATION; GENETIC PROCEDURES; GENOTYPE; HEMOCHROMATOSIS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IRON BLOOD LEVEL; IRON METABOLISM; IRON OVERLOAD; LIFE EXPECTANCY; LIVER BIOPSY; LIVER DISEASE; PHENOTYPE; PHLEBOTOMY; RELATIVE; REVIEW; SCREENING; SYMPTOM;

EID: 0032991330     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.1999.tb00014.x     Document Type: Review

References (81)

1. OLYNYK J K, BACON B R. Hereditary haemochromatosis. Detecting and correcting iron overload. Postgrad Med 1994; 96: 151-65.
2. nd ed. Paris: Balliere, 1889: 665.
3. SIMON M, BOUREL M, FAUCHET R, et al. Idiopathic haemochromatosis. Demonstration of recessive transmission and early detection by family HLA typing. N Engl J Med 1977; 297: 1017-21.
4. FEDER J N, GNIRKE A, THOMAS W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-409.
5. BEUTLER E, GELBART T, WEST C, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996; 22: 187-94.
6. JAZWINSKA E C, CULLEN L M, BUSFIELD F, et al. Haemochromatosis and HLA-H. Nat Genet 1996; 14: 249-51.
7. JOUANOLLE A-M, GANDON G, JEZEQUAL P, et al. Haemochromatosis and HLA-H. Nat Genet 1996; 14: 251-2.
8. BARTON J C, SHIH W W, SAWADA-HIRAI R, et al. Genetic and clinical description of hemochromatosis probands and heterozygotes: evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis. Blood Cells Mol Dis 1997; 23: 135-45.
9. ADAMS P C, CAMPION M L, GWANDON G, et al. Clinical and family studies in genetic hemochromatosis: microsatellite and HFE studies in five atypical families. Hepatology 1997; 26: 986-90.
10. THE U K HAEMOCHROMATOSIS CONSORTIUM. A simple genetic test identifies 90% of UK patients with haemochromatosis. Gut 1997; 41: 841-4.
11. BOROT N, ROTHER M-P, MALFROY L, et al. Mutations in the MHC class I-like candidate gene for hemochromatosis in French patients. Immunogenetics 1997; 45: 320-4.
12. CARELLA M, D'AMBROSIO L, TOTARO A, et al. Mutation analysis of the HLA-H gene in Italian haemochromatosis patients. Am J Hum Genet 1997; 60: 828-32.
13. CARDOSO E M P, STAL P. HAGEN K, et al. HFE mutations in patients with hereditary haemochromatosis in Sweden. J Intern Med 1998; 243: 203-8.
14. ROSSI E, HENDERSON S, CHIN C, et al. Genotyping as a diagnostic aid in genetic haemochromatosis. J Gastroenterol Hepatol, in press.
15. ZHOU X Y, TOMATSU S, FLEMING R E, et al. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci USA 1998; 95: 2492-7.
16. FEDER J N, TSUCHIHASHI Z, IRRINKI A, et al. The hemochromatosis founder mutation in HLA-H disrupts β2 microglobulin interaction and cell surface expression. J Biol Chem 1997; 272: 14025-8.
17. 2-microglobulin knockout mice recapitulates hereditary hemochromatosis in man. J Exp Med 1996; 184: 1975-85.
18. PARKKILA S, WAHEED A, BRITTON R S, et al. Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci USA 1997; 94: 13198-202.
19. 2-microglobulin intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA 1997; 94: 12384-9.
20. FEDER J N, PENNY D M, IRRINKI A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998; 95: 1472-7.
21. BACON B R, POWELL L W, ADAMS P C, et al. Molecular medicine and haemochromatosis: At the crossroads. Gastroenterology 1999; 116: 193-207.
22. MERRYWEATHER-CLARKE A, POINTON J, SHERMAN J, et al. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34: 275-8.
23. OLYNYK J, CULLEN D, ROSSI R, et al. Clinical expression of the hemochromatosis mutation C282Y in the Busselton population. Hepatology 1998; 28: 528A (abstract).
24. GORDEUK V R, McLAREN C E. LOOKER A C, et al. Distribution of transferrin saturation in the African-American population. Blood 1998; 91: 2175-9.
25. MONAGHAN K G, RYBICKI B A, SHURAFA M, et al. Mutation analysis of the HFE gene associated with hereditary hemochromatosis in African Americans. Am J Hematol 1998; 58: 213-7.
26. CULLEN L M, GAO X, EASTEAL S, et al. The hemochromatosis 845 G to A and 187 C to G mutations: prevalence in non-caucasian populations. Am J Hum Genet 1998; 62: 1403-7.
27. CHANG J G, LIU T C, LIN S F. Rapid diagnosis of the HLA-H gene Cys282Tyr mutation in hemochromatosis by polymerase chain reaction - a very rare mutation in the Chinese population. Blood 1997; 89: 3492-3.
28. GEORGE D K, GOLDWURM S, MACDONALD G A, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-8.
29. ROBERTS A G, WHATLEY S D, MORGAN R R, et al. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997; 349: 321-3.
30. STUART K A, BUSFIELD F, JAZWINSKA E C, et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 1998; 28: 404-9.
31. ELDER G H, WORWOOD M. Mutations in the hemochromatosis gene, porphyria cutanea tarda, and iron overload. Hepatology 1998; 27: 289-91.
32. SAMPIETRO M, PIPERNO A, LUPICA L, et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 1998; 27: 181-4.
33. SMITH B C, GORVE J, GUZAIL M A, et al. Heterozygosity for hereditary hemochromatosis is associated with fibrosis in chronic hepatitis C. Hepatology 1998; 27: 1695-9.
34. GROVE J, DALY A K, BURT A D, et al. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut 1998; 46: 262-6.
35. BACON B R, OLYNYK J K, BRUNT E M, et al. HFE genotype in patients with hemochromatosis and in patients with liver disease. Ann Intern Med, in press.
36. EDWARDS C Q, GRIFFEN L M, GOLDGAR D, et al. Prevalence of haemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355-62.
37. BACON B R, TAVILL A S. Hemochromatosis and the iron overload syndromes. In: Zakim D, Boyer TD eds. Hepatology: a Textbook of liver disease. Philadelphia: WB Saunders Co., 1996: 1439-72.
38. CRAWFORD D H, JAZWINSKA E C, CULLEN L M, et al. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology 1998; 114: 1003-8.
39. ADAMS P C, CHAKRABARTI S. Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria. Gastroenterology 1998; 114: 319-23.
40. MURA C, NOUSBAUM J B, VERGER P, et al. Phenotype-genotype correlation in haemochromatosis subjects. Hum Genet 1997; 101: 271-6.
41. ADAMS P C, KERTESZ A E, VALBERG L S. Clinical presentation of haemochromatosis: a changing scene. Am J Med 1991; 90: 445-9.
42. ADAMS P C, SPEECHLEY M, KERTESZ A E. Long-term survival analysis in hereditary haemochromatosis. Gastroenterology 1991; 101: 368-72.
43. EDWARDS C G, CARTWRIGHT G E, SKOLNICK M E, et al. Homozygosity for haemochromatosis: clinical manifestations. Ann Intern Med 1980; 93: 519-25.
44. NIEDERAU C, FISCHER R, SONNENBERG A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary haemochromatosis. N Engl J Med 1985; 313: 1256-62.
45. HUAUX J P, GEUBEL A, KOCH M C, et al. The arthritis of haemochromatosis. A review of 25 cases with special reference to chondrocalcinosis, and a comparison with patients with primary hyperparathyroidism and controls. Clin Rheumatol 1986; 5: 317-24.
46. OLYNYK J, HALL P, AHERN M, et al. Screening for genetic haemochromatosis in a rheumatology clinic. Aust NZ J Med 1994; 24: 22-5.
47. NIEDERAU C, FISCHER R, PURSCHEL A, et al. Long term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107-19.
48. BRITTON R S, RAMM G A, OLYNYK J, et al. Pathophysiology of iron toxicity. Adv Exp Med Biol 1994; 356: 239-53.
49. GUALDI R, CASALGRANDI G, MONTOSI G, et al. Excess iron into hepatocytes is required for activation of collagen type 1 gene during experimental siderosis. Gastroenterology 1994; 104: 1118-24.
50. MAHER J J, ZIA S. TZAGARAKIS C. Acetaldehyde-induced stimulation of collagen synthesis and gene expression is dependent on conditions of cell culture: studies with rat lipocytes and fibroblasts. Alcohol Clin Exp Res 1994; 18: 403-9.
51. MAHER J J, TZAGARAKIS C, GIMENEZ A. et al. Malondialdehyde stimulates collagen production by hepatic lipocytes only upon activation in primary culture. Alcohol Alcohol 1994; 29: 605-10.
52. LEONARDUZZI G, SCAVAZZA A, BIASI F, et al. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor betal expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J 1997; 11: 851-7.
53. PAROLA M, MURACA R, DIANZANI I, et al. Vitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver. FEBS Lett 1992; 308: 267-70.
54. BRITTON R S, EDLING J E, GRISHAM M B, et al. Hepatic DNA damage in rats with chronic dietary iron overload. In: Proceedings of the Third International Conference on Haemochromatosis. 1991: 4.
55. NORDENSON I, RITTER B, BECKMAN A, et al. Idiopathic haemochromatosis and chromosomal damage. Hum Hered 1992; 42: 143-5.
56. LOWES K N, BRENNAN B A, YEOH G C, et al. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol 1999; 154: 537-41.
57. PHELPS G, CHAPMAN I, HALL P, et al. Prevalence of genetic haemochromatosis among diabetic patients. Lancet 1989; 29: 233-4.
58. BASSETT M L, HALLIDAY J W, BRYANT S, et al. Screening for hemochromatosis. Ann N Y Acad Sci 1988; 526: 274-89.
59. BIELBY J, OLYNYK J, CHIN S, et al. Transferrin index: an alternative method for calculating the iron saturation of transferrin. Clin Chem 1992; 38: 2078-81.
60. BURT M J, GEORGE P M, UPTON J D, et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut 1998; 43: 830-6.
61. McLAREN C E, McLACHLAN G J, HALLIDAY J W, et al. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. Gastroenterology 1998; 114: 543-9.
62. LEGGETT B A, HALLIDAY J W, BROWN N N, et al. Prevalence of haemochromatosis amongst asymptomatic Australians. BrJ Haematol 1990; 74: 525-30.
63. GUYADER D, JACQUELINET C, MOIRAND R, et al. Non-invasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998; 115: 929-36.
64. MENDLER M H, MOIRAND R, TURLIN B, et al. Study of HFE mutations in the "dysmetabolic iron overload syndrome". Hepatology 1998; 28; 419A (abstract).
65. OLYNYK J, O'NEILL R, BRITTON R S, et al. Determination of hepatic iron concentration in fresh and paraffin-embedded tissue: diagnostic implications. Gastroenterology 1994; 106: 674-7.
66. BRUNT E M, BRITTON R S, OLYNYK J K, et al. Iron grading: a proposal for a histologic system that includes the pattern, location and grade of stainable iron. Hepatology 1998; 28: 423A (abstract).
67. BASSETT M L, HALLIDAY J W, POWELL L W. Value of iron measurement in early haemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986; 6: 24-9.
68. SUMMERS K M, HALLIDAY J W, POWELL L W. Identification of homozygous haemochromatosis subjects by measurement of hepatic iron index. Hepatology 1990; 12: 20-5.
69. OLYNYK J, HALL P, SALLIE R, et al. Computerized measurement of iron in liver biopsies: comparison with biochemical iron measurement. Hepatology 1990; 12: 26-30.
70. BONKOVSKY H L, SLAKER D P, BILLS E D, et al. Usefulness and limitations of laboratory and hepatic imaging studies in iron storage disease. Gastroenterology 1990; 99: 1079-91.
71. SALLIE R W, REED W D, SHILKIN K B. Confirmation of the efficacy of hepatic tissue iron index in differentiating genetic haemochromatosis from alcoholic liver disease complicated by alcoholic haemosiderosis. Gut 1991; 32: 207-10.
72. ADAMS P C, KERTESZ A E, VALBERG L S. Rate of iron reaccumulation in hereditary hemochromatosis: implications for venesection therapy. J Clin Gastroenterol 1993; 16: 207-10.
73. OLYNYK J K, LUXON B A, BRITTON R S, et al. Hepatic iron concentration in hereditary hemochromatosis does not saturate or accurately predict phlebotomy requirements. Am J Gastroenterol 1998; 93: 346-50.
74. BURKE W, THOMSON E, KHOURY M J, et al. Hereditary hemochromatosis: gene discovery and implications for population-based screening. JAMA 1998; 280: 172-8.
75. ADAMS P C. Implications of genotyping of spouses to limit investigation in children in genetic hemochromatosis. Clin Genet 1998; 53: 176-8.
76. PHATAK P D, GUZMAN G, WOLL J E, et al. Cost-effectiveness of screening for hereditary haemochromatosis. Arch Intern Med 1994; 154: 769-76.
77. BALAN V, BALDUS W, FAIRBANKS V, et al. Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients. Gastroenterology 1994; 107: 453-9.
78. BUFFONE G J, BECK J R. Cost-effectiveness analysis for evaluation of screening programs: hereditary haemochromatosis Clin Chem 1994; 40: 1631-6.
79. ADAMS P C, GREGOR J C, KERTESZ A E, et al. Screening blood donors for hereditary hemochromatosis: a decision analysis model based on a 30-year database. Gastroenterology 1995; 109: 177-88.
80. MASON J, DRUMMOND M, TORRANCE G. Some guidelines on the use of cost effectiveness league tables. BMJ 1993; 306: 570-2.
81. COLLINS R, PETO R, MACMAHON S, et al. Blood pressure, stroke, and coronary disease. II. Short-term reductions in blood pressure: overview of randomised trials in their epidemiologic context. Lancet 1990; 335: 827-38.